Inmune Bio, Inc.

Inmune Bio, Inc. is a clinical-stage biotechnology company developing immunology-based therapies for inflammatory, neurodegenerative, and rare disease indications. Its pipeline includes CORDStrom and XPro, with the company still pre-commercial and dependent on clinical progress, regulatory milestones, and external financing.

−94 598,0 %

−91 866,0 %

+257,1 %

3.55

3.55

— Inmune Bio, Inc.
%
CORDStrom60% Cell therapy program focused on RDEB and related rare disease treatment pathways.
XPro25% Anti-inflammatory biologic program aimed at neuroinflammation and CNS-related disorders.
Collaborations and licensing10% Revenue from license agreements, data access arrangements, and related milestones.
Other research programs5% Earlier-stage discovery and preclinical work supporting future pipeline expansion.

The company does not sell broadly to end consumers; its economic customers are patients, physicians, hospitals, and...

  • Rare disease patients and caregiversprimary

    Patients with RDEB and other severe unmet-need conditions who would use CORDStrom if approved.

  • Clinical investigators and hospitalsprimary

    Trial sites that enroll patients, administer study treatment, and generate efficacy/safety data.

  • Regulatory agenciesprimary

    FDA, EMA, and MHRA review the company’s CMC, safety, and efficacy packages and determine approval.

  • Strategic partners and licensorssecondary

    Third parties that may fund, license, or commercialize programs or provide clinical data access.

Inmune Bio is headquartered in the United States, but a meaningful part of its research and development spending occurs...

  • •United States is the corporate and reporting base
  • •R&D spending is significant in the United Kingdom and Australia
  • •Regulatory work spans the FDA, EMA, and MHRA
  • •Foreign currency swings affect UK and Australia operating costs
  • •Current revenue is minimal and not geographically diversified

The company’s strategy is to advance its lead programs through clinical development, secure regulatory designations,...

01
Advance CORDStrom toward marketing authorizationshort-term

Approval would unlock commercialization, exclusivity benefits, and potential PRV value.

02
Use external clinical data and partnershipsshort-term

Licensing and collaborations can accelerate development and reduce internal spend.

03
Fund operations through equity and strategic financingshort-term

The company has recurring losses and substantial doubt about going concern.

04
Build clinical evidence for XPro and other programsmedium-term

Pipeline breadth can create future value beyond a single asset.

Inmune Bio faces classic clinical-stage biotech risks: trial failure, regulatory delay, and uncertainty around whether...

critical

Going concern and liquidity shortfall

The company has recurring net losses and negative cash flows and may need additional capital before commercialization.

Scope
Cash runway and ability to fund clinical development
Materiality
high
high

Clinical development failure

Pipeline value depends on positive trial outcomes for CORDStrom and XPro.

Scope
Lead asset approval probability
Materiality
high
high

Regulatory and CMC execution risk

FDA/EMA/MHRA feedback can require additional studies, manufacturing changes, or delays.

Scope
Approval timing and development cost
Materiality
high
medium

Foreign exchange volatility

R&D is incurred in Australia and the United Kingdom, creating translation and transaction exposure.

Scope
Operating expenses and foreign subsidiary balances
Materiality
medium
Revenue recognition on license agreements
Can create lumpy quarterly revenue and comparability issues
Impairment of acquired in-process R&D
Non-cash charge can materially widen reported losses
Stock-based compensation
Raises operating expenses and affects loss metrics
Foreign currency translation
Moves expenses, assets, and liabilities in reported U.S. dollars

Evommune, Inc.

EVMN · Pharmaceutical Preparations

IN8BIO, INC.

INAB · Biological Products, (No Diagnostic Substances)

ImageneBio, Inc.

IMA · Biological Products, (No Diagnostic Substances)

Imunon, Inc.

IMNN · Pharmaceutical Preparations

Instil Bio, Inc.

TIL · Biological Products, (No Diagnostic Substances)

ImmunityBio, Inc.

IBRX · Biological Products, (No Diagnostic Substances)

: 28.4.2026